一种用于治疗尿崩症的血管加压素类似物。
A vasopressin analogue in treatment of diabetes insipidus.
作者信息
Kauli R, Laron Z
出版信息
Arch Dis Child. 1974 Jun;49(6):482-5. doi: 10.1136/adc.49.6.482.
Six children, 3 adolescents, and 3 adults with vasopressin-sensitive diabetes insipidus were treated with a vasopressin analogue, DDAVP (1-deamino-8-D-arginine vasopressin), at a daily dose ranging from 5 to 20 μg administered twice a day intranasally. The period of follow-up of these patients has been from 3 months to 1 year. DDAVP was effective in maintaining normal diuresis and normal urine concentration during both day and night. No local or vasopressor side effects were observed. Compared to other antidiuretic drugs, such as nasal pitressin powder, lysine-vasopressin nasal spray, or pitressin tannate injections, used previously by the patients, DDAVP proved to be superior in the control of the diabetes insipidus and in the subjective feeling of the patients. It is concluded that DDAVP is the drug of choice in the treatment of vasopressinsensitive diabetes insipidus.
6名儿童、3名青少年和3名患有血管加压素敏感性尿崩症的成人接受了血管加压素类似物去氨加压素（1-去氨基-8-D-精氨酸血管加压素）治疗，每日剂量为5至20微克，每天经鼻给药两次。这些患者的随访期为3个月至1年。去氨加压素在维持白天和夜间正常利尿及正常尿液浓缩方面有效。未观察到局部或血管加压副作用。与患者先前使用的其他抗利尿药物，如鼻用垂体后叶粉、赖氨酸加压素鼻喷雾剂或鞣酸加压素注射液相比，去氨加压素在控制尿崩症及患者主观感受方面被证明更具优势。结论是，去氨加压素是治疗血管加压素敏感性尿崩症的首选药物。
Zotero 插件